Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever

This study has been completed.
Information provided by:
National Taiwan University Hospital Identifier:
First received: December 16, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted
The soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) was an established biomarker useful for infection in non-neutropenic patients. In this study, we tested sTREM-1 in the patients with neutropenic fever. Pro-calcitonin (PCT) and C-reactive protein (CRP) were also measured. We planned to investigate and explore the role of sTREM-1 in early diagnosis of infection in patients with neutropenic fever.

Neutropenic Fever

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Biospecimen Retention:   Samples With DNA
whole blood

Enrollment: 75
Study Start Date: October 2008
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Detailed Description:
Patients with hematological malignancies developed neutropenia after chemotherapy. We checked the serum level of sTREM-1 in patients with neutropenic fever. Those patients were classified to 2 groups: documented infection or low likelihood of infection. Their sTREM-1 level was measured and was compared with other biomarker such as CRP and procalcitonin. The value of sTREM-1 for diagnosis of infection in patients with neutropenic fever was thus evaluated.

Ages Eligible for Study:   18 Years to 84 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with hematological malignancy developing neutropenic fever after chemotherapy

Inclusion Criteria:

  • chemotherapy-related neutropenia (granulocytes < 0.5 × 109/l or leukocytes < 1 × 109/l) and fever (body temperature > 38.0°C over a 6 hour observation period or body temperature ≥ 38.5°C once.

Exclusion Criteria:

  • prolonged fever before presenting for admission,
  • antibiotics therapy in the past 72 hours,
  • more than two sites of infectious focus,
  • concomitant solid organ malignancy and blast in hemogram.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01034059

Sponsors and Collaborators
National Taiwan University Hospital
Principal Investigator: Szu-Chun Hsu, MD Department of Laboratory Medicine, National Taiwan University Hospital and College of Medicine, Taipei
  More Information

Responsible Party: Szu-Chun Hsu, Department of Laboratory Medicine, National Taiwan University Hospital and College of Medicine, Taipei Identifier: NCT01034059     History of Changes
Other Study ID Numbers: 200806051R 
Study First Received: December 16, 2009
Last Updated: December 16, 2009
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Febrile Neutropenia
Body Temperature Changes
Signs and Symptoms
Leukocyte Disorders
Hematologic Diseases processed this record on October 25, 2016